Back to Search
Start Over
NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses
- Source :
- The Journal of Clinical Investigation, Vol 132, Iss 19 (2022)
- Publication Year :
- 2022
- Publisher :
- American Society for Clinical Investigation, 2022.
-
Abstract
- NVX-CoV2373 is an adjuvanted recombinant full-length SARS-CoV-2 spike trimer protein vaccine demonstrated to be protective against COVID-19 in efficacy trials. Here we demonstrate that vaccinated individuals made CD4+ T cell responses after 1 and 2 doses of NVX-CoV2373, and a subset of individuals made CD8+ T cell responses. Characterization of the vaccine-elicited CD8+ T cells demonstrated IFN-γ production. Characterization of the vaccine-elicited CD4+ T cells revealed both circulating T follicular helper (cTfh) cells and Th1 cells (IFN-γ+, TNF-α+, and IL-2+) were detectable within 7 days of the primary immunization. Spike-specific CD4+ T cells were correlated with the magnitude of the later SARS-CoV-2–neutralizing antibody titers, indicating that robust generation of CD4+ T cells, capable of supporting humoral immune responses, may be a key characteristic of NVX-CoV2373 that utilizes Matrix-M adjuvant.
- Subjects :
- Immunology
Medicine
Subjects
Details
- Language :
- English
- ISSN :
- 15588238
- Volume :
- 132
- Issue :
- 19
- Database :
- Directory of Open Access Journals
- Journal :
- The Journal of Clinical Investigation
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.1bcb00519ff408b99a843d3d67b9a38
- Document Type :
- article
- Full Text :
- https://doi.org/10.1172/JCI160898